This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Al-Madhoun, A. S. Articles by Eriksson, S. Search for Related Content PubMed PubMed Citation Articles by Al-Madhoun, A. S. Articles by Eriksson, S.

Evaluation of Human Thymidine Kinase 1 Substrates as New Candidates for Boron Neutron Capture Therapy

¹ Department of Molecular Biosciences, Division of Veterinary Medical Biochemistry, Swedish University of Agricultural Sciences, Biomedical Center, Uppsala, Sweden; and ² College of Pharmacy and ³ Department of Pathology, The Ohio State University, Columbus, Ohio

Thymidine analogs containing o-carboranylalkyl groups at the 3-position were screened as potential substrates for human thymidine kinase 1 (TK1), an enzyme that is selectively expressed in a variety of rapidly proliferating cells, including tumor cells. On the basis of previous studies, 12 of these were identified as potential delivery agents for boron neutron capture therapy, a therapeutic method used for the treatment of high-grade brain tumors. Compound 4 with a pentylene spacer between the o-carborane cage and the thymidine scaffold and compound 10, which has an additional dihydroxypropyl substituent at the o-carborane cage, were the best substrates for TK1 with k_cat/K_m values of 27% and 36% relative to that of thymidine, respectively. These compounds showed partial competitive inhibition for thymidine phosphorylation by TK1. Neither compound was a substrate of recombinant human thymidine phosphorylase nor were their respective 5'-monophosphates substrates of 5'-deoxynucleotidase 1, thereby indicating potential in vivo stability. The octanol/water partition coefficient for compound 10 was 2.09, suggesting that it has excellent physiochemical properties for crossing the blood brain barrier and penetrating brain tissue. The in vitro cytotoxic effect of the 12 analogs was moderate to low in mammalian cell cultures with IC₅₀ values between 10 and 160 µmol/L. Compounds 4 and 10 were taken up selectively and retained by the murine fibroblast L929 cell line, in contrast to its TK1-deficient variant. These findings suggest that compound 10 is a promising candidate for selective delivery of boron-10 to malignant cells, and additional in vivo studies are planned to evaluate it for boron neutron capture therapy of brain tumors.

This article has been cited by other articles:

				A. Morgenroth, S. Deisenhofer, G. Glatting, F. H-G. Kunkel, C. Dinger, B. Zlatopolskiy, A. T.J. Vogg, T. Kull, and S. N. Reske Preferential Tumor Targeting and Selective Tumor Cell Cytotoxicity of 5-[131/125I]Iodo-4'-Thio-2'-Deoxyuridine Clin. Cancer Res., November 15, 2008; 14(22): 7311 - 7319. [Abstract] [Full Text] [PDF]

				R. F. Barth, W. Yang, G. Wu, M. Swindall, Y. Byun, S. Narayanasamy, W. Tjarks, K. Tordoff, M. L. Moeschberger, S. Eriksson, et al. Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors PNAS, November 11, 2008; 105(45): 17493 - 17497. [Abstract] [Full Text] [PDF]

				R. F. Barth, J. A. Coderre, M. G. H. Vicente, and T. E. Blue Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects Clin. Cancer Res., June 1, 2005; 11(11): 3987 - 4002. [Abstract] [Full Text] [PDF]

				R. F. Barth, W. Yang, A. S. Al-Madhoun, J. Johnsamuel, Y. Byun, S. Chandra, D. R. Smith, W. Tjarks, and S. Eriksson Boron-Containing Nucleosides as Potential Delivery Agents for Neutron Capture Therapy of Brain Tumors Cancer Res., September 1, 2004; 64(17): 6287 - 6295. [Abstract] [Full Text] [PDF]